Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

IDEAYA Biosciences (IDYA) Retained Earnings: 2019-2025

Historic Retained Earnings for IDEAYA Biosciences (IDYA) over the last 7 years, with Sep 2025 value amounting to -$653.3 million.

  • IDEAYA Biosciences' Retained Earnings fell 32.64% to -$653.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$653.3 million, marking a year-over-year decrease of 32.64%. This contributed to the annual value of -$622.8 million for FY2024, which is 78.79% down from last year.
  • According to the latest figures from Q3 2025, IDEAYA Biosciences' Retained Earnings is -$653.3 million, which was up 15.43% from -$772.5 million recorded in Q2 2025.
  • In the past 5 years, IDEAYA Biosciences' Retained Earnings registered a high of -$136.0 million during Q1 2021, and its lowest value of -$772.5 million during Q2 2025.
  • For the 3-year period, IDEAYA Biosciences' Retained Earnings averaged around -$479.4 million, with its median value being -$440.7 million (2024).
  • Data for IDEAYA Biosciences' Retained Earnings shows a maximum YoY plummeted of 79.16% (in 2025) over the last 5 years.
  • Over the past 5 years, IDEAYA Biosciences' Retained Earnings (Quarterly) stood at -$176.7 million in 2021, then slumped by 33.19% to -$235.4 million in 2022, then crashed by 47.99% to -$348.4 million in 2023, then plummeted by 78.79% to -$622.8 million in 2024, then slumped by 32.64% to -$653.3 million in 2025.
  • Its Retained Earnings stands at -$653.3 million for Q3 2025, versus -$772.5 million for Q2 2025 and -$695.0 million for Q1 2025.